Blanchard C, Rothenberg ME Basic pathogenesis of eosinophilic esophagitis. Gastrointest Endosc Clin N Am. 2008 Jan;18(1):133-43; x. Review.
Blanchard C, Wang N, Rothenberg ME Eosinophilic esophagitis: pathogenesis, genetics, and therapy. J Allergy Clin Immunol. 2006 Nov;118(5):1054-9. Epub 2006 Sep 18. Review.
Chehade M, Sampson HA, Morotti RA, Magid MS Esophageal subepithelial fibrosis in children with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2007 Sep;45(3):319-28.
Dohil R, Newbury R, Fox L, Bastian J, Aceves S Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology. 2010 Aug;139(2):418-29. doi: 10.1053/j.gastro.2010.05.001. Epub 2010 May 7.
El-Swefy S, Hassanen SI Improvement of hepatic fibrosis by leukotriene inhibition in cholestatic rats. Ann Hepatol. 2009 Jan-Mar;8(1):41-9.
Izumo T, Kondo M, Nagai A Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice. Life Sci. 2007 Apr 24;80(20):1882-6. Epub 2007 Mar 12.
Lucendo AJ, Bellón T, Lucendo B The role of mast cells in eosinophilic esophagitis. Pediatr Allergy Immunol. 2009 Sep;20(6):512-8. doi: 10.1111/j.1399-3038.2008.00798.x. Epub 2008 Aug 4. Review.
Rothenberg ME Biology and treatment of eosinophilic esophagitis. Gastroenterology. 2009 Oct;137(4):1238-49. doi: 10.1053/j.gastro.2009.07.007. Epub 2009 Aug 15. Review.
Wershil BK Exploring the role of mast cells in eosinophilic esophagitis. Immunol Allergy Clin North Am. 2009 Feb;29(1):189-95, xiii. doi: 10.1016/j.iac.2008.09.006. Review.
A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
